
News|Videos|May 4, 2026
7 Cardiology Headlines You Missed in April 2026
Author(s)Ryan Livingston
Fact checked by: Chelsie Derman
April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.
Advertisement
Advertisement
Despite a relatively quiet month from the
Related to this article

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
Advertisement
Advertisement

